HRYZ Biotech

Executive Summary

HRYZ Biotech is a clinical-stage biotechnology company based in Shanghai, China, dedicated to developing novel antibody-based therapeutics for oncology and immunology. Founded in 2016, the company leverages advanced antibody engineering to create differentiated candidates targeting key immune checkpoints and tumor antigens, addressing significant unmet medical needs. With a pipeline of investigational assets in Phase 2 clinical trials, HRYZ Biotech aims to advance its lead programs through key data readouts and potential regulatory milestones. The company operates in the competitive landscape of immuno-oncology, but its focus on novel targets and engineering capabilities positions it for potential value creation. As a private entity with 50-200 employees, HRYZ Biotech continues to progress its pipeline while seeking strategic partnerships or financing to support its development programs.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for lead oncology candidate50% success
• Q1 2027IND filing for new immunology asset70% success
• H2 2026Strategic partnership or licensing deal35% success